Michael Yee
Stock Analyst at Jefferies
(4.03)
# 628
Out of 4,413 analysts
61
Total ratings
44.68%
Success rate
15.03%
Average return
Main Sectors:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Reiterates: Buy | $125 | $110.31 | +13.32% | 6 | Apr 9, 2024 | |
| NUVB Nuvation Bio | Upgrades: Buy | $1.4 → $10 | $2.99 | +234.45% | 3 | Mar 27, 2024 | |
| CRGX CARGO Therapeutics | Maintains: Buy | $28 → $32 | $19.10 | +67.54% | 2 | Mar 22, 2024 | |
| IMRX Immuneering | Downgrades: Hold | $16 → $3 | $1.42 | +111.27% | 2 | Mar 15, 2024 | |
| CERE Cerevel Therapeutics Holdings | Downgrades: Hold | $40 → $45 | $42.71 | +5.36% | 1 | Dec 22, 2023 | |
| BEAM Beam Therapeutics | Downgrades: Hold | $75 → $30 | $21.22 | +41.38% | 2 | Dec 8, 2023 | |
| ALXO ALX Oncology Holdings | Upgrades: Buy | $8 → $18 | $17.02 | +5.76% | 3 | Dec 8, 2023 | |
| AMRN Amarin Corporation | Downgrades: Hold | $3 → $1 | $0.92 | +8.59% | 4 | Oct 25, 2023 | |
| SRRK Scholar Rock Holding | Upgrades: Buy | $8 → $20 | $14.67 | +36.33% | 2 | Oct 25, 2023 | |
| AMGN Amgen | Reiterates: Buy | $310 | $273.94 | +13.16% | 4 | Oct 12, 2023 | |
| KOD Kodiak Sciences | Downgrades: Hold | $3 | $3.21 | -6.54% | 2 | Jul 24, 2023 | |
| ALGS Aligos Therapeutics | Upgrades: Buy | $2.5 → $3 | $0.77 | +292.16% | 1 | Jan 6, 2023 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Hold | n/a | $392.81 | - | 3 | Dec 19, 2022 | |
| BIIB Biogen | Maintains: Buy | $325 → $350 | $214.82 | +62.93% | 4 | Nov 30, 2022 | |
| VTYX Ventyx Biosciences | Initiates: Buy | n/a | $3.74 | - | 1 | Nov 15, 2021 | |
| IMCR Immunocore Holdings | Initiates: Buy | n/a | $59.08 | - | 1 | Mar 2, 2021 | |
| FGEN FibroGen | Downgrades: Hold | n/a | $1.12 | - | 2 | Mar 2, 2021 | |
| ESPR Esperion Therapeutics | Downgrades: Hold | n/a | $1.97 | - | 3 | Feb 12, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | n/a | $20.34 | - | 3 | Feb 12, 2021 | |
| ASMB Assembly Biosciences | Downgrades: Hold | $120 | $12.47 | +862.31% | 2 | Nov 6, 2020 | |
| SDGR Schrödinger | Upgrades: Buy | n/a | $24.38 | - | 2 | Oct 12, 2020 | |
| INBX Inhibrx | Initiates: Buy | n/a | $34.04 | - | 1 | Sep 14, 2020 | |
| DNLI Denali Therapeutics | Initiates: Buy | n/a | $15.44 | - | 1 | Feb 24, 2020 | |
| AXON Axon Enterprise | Upgrades: Buy | n/a | $313.66 | - | 2 | Dec 17, 2018 | |
| URGN UroGen Pharma | Assumes: Buy | n/a | $13.82 | - | 2 | Nov 8, 2018 | |
| GILD Gilead Sciences | Upgrades: Buy | n/a | $65.20 | - | 2 | Jan 26, 2018 |
Moderna
Apr 9, 2024
Reiterates: Buy
Price Target: $125
Current: $110.31
Upside: +13.32%
Nuvation Bio
Mar 27, 2024
Upgrades: Buy
Price Target: $1.4 → $10
Current: $2.99
Upside: +234.45%
CARGO Therapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $28 → $32
Current: $19.10
Upside: +67.54%
Immuneering
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $1.42
Upside: +111.27%
Cerevel Therapeutics Holdings
Dec 22, 2023
Downgrades: Hold
Price Target: $40 → $45
Current: $42.71
Upside: +5.36%
Beam Therapeutics
Dec 8, 2023
Downgrades: Hold
Price Target: $75 → $30
Current: $21.22
Upside: +41.38%
ALX Oncology Holdings
Dec 8, 2023
Upgrades: Buy
Price Target: $8 → $18
Current: $17.02
Upside: +5.76%
Amarin Corporation
Oct 25, 2023
Downgrades: Hold
Price Target: $3 → $1
Current: $0.92
Upside: +8.59%
Scholar Rock Holding
Oct 25, 2023
Upgrades: Buy
Price Target: $8 → $20
Current: $14.67
Upside: +36.33%
Amgen
Oct 12, 2023
Reiterates: Buy
Price Target: $310
Current: $273.94
Upside: +13.16%
Kodiak Sciences
Jul 24, 2023
Downgrades: Hold
Price Target: $3
Current: $3.21
Upside: -6.54%
Aligos Therapeutics
Jan 6, 2023
Upgrades: Buy
Price Target: $2.5 → $3
Current: $0.77
Upside: +292.16%
Vertex Pharmaceuticals
Dec 19, 2022
Downgrades: Hold
Price Target: n/a
Current: $392.81
Upside: -
Biogen
Nov 30, 2022
Maintains: Buy
Price Target: $325 → $350
Current: $214.82
Upside: +62.93%
Ventyx Biosciences
Nov 15, 2021
Initiates: Buy
Price Target: n/a
Current: $3.74
Upside: -
Immunocore Holdings
Mar 2, 2021
Initiates: Buy
Price Target: n/a
Current: $59.08
Upside: -
FibroGen
Mar 2, 2021
Downgrades: Hold
Price Target: n/a
Current: $1.12
Upside: -
Esperion Therapeutics
Feb 12, 2021
Downgrades: Hold
Price Target: n/a
Current: $1.97
Upside: -
Prothena Corporation
Feb 12, 2021
Upgrades: Buy
Price Target: n/a
Current: $20.34
Upside: -
Assembly Biosciences
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $12.47
Upside: +862.31%
Schrödinger
Oct 12, 2020
Upgrades: Buy
Price Target: n/a
Current: $24.38
Upside: -
Inhibrx
Sep 14, 2020
Initiates: Buy
Price Target: n/a
Current: $34.04
Upside: -
Denali Therapeutics
Feb 24, 2020
Initiates: Buy
Price Target: n/a
Current: $15.44
Upside: -
Axon Enterprise
Dec 17, 2018
Upgrades: Buy
Price Target: n/a
Current: $313.66
Upside: -
UroGen Pharma
Nov 8, 2018
Assumes: Buy
Price Target: n/a
Current: $13.82
Upside: -
Gilead Sciences
Jan 26, 2018
Upgrades: Buy
Price Target: n/a
Current: $65.20
Upside: -